Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 30;13(4):608.
doi: 10.3390/jpm13040608.

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer

Wojciech A Cieślikowski  1 , Piotr Milecki  2 , Monika Świerczewska  3 , Agnieszka Ida  1 , Michał Kasperczak  1 , Agnieszka Jankowiak  3 , Michał Nowicki  3 , Klaus Pantel  4 , Catherine Alix-Panabières  5 , Maciej Zabel  6   7 , Andrzej Antczak  1 , Joanna Budna-Tukan  3
Affiliations

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer

Wojciech A Cieślikowski et al. J Pers Med. .

Abstract

The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch® system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56-74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch® system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter.

Keywords: circulating tumor cells; metastasis-free survival; overall survival; prognosis; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
MFS estimates in 85 patients with localized PCa at baseline: (a) entire cohort; (b) by cT status at the baseline.
Figure 2
Figure 2
OS estimates in 104 high-risk PCa patients: (a) entire cohort; (b) by baseline CTC count ≥ 1 determined with the CellSearch® system; (c) by baseline Gleason sum; (d) by baseline cT status; (e) by the presence of metastases at the baseline.
Figure 2
Figure 2
OS estimates in 104 high-risk PCa patients: (a) entire cohort; (b) by baseline CTC count ≥ 1 determined with the CellSearch® system; (c) by baseline Gleason sum; (d) by baseline cT status; (e) by the presence of metastases at the baseline.
Figure 3
Figure 3
OS estimates in 85 patients with localized PCa at baseline: (a) entire cohort; (b) by baseline CTC count ≥ 1 determined with the CellSearch® system.
See this image and copyright information in PMC

References

    1. Wong M.C.S., Goggins W.B., Wang H.H.X., Fung F.D.H., Leung C., Wong S.Y.S., Ng C.F., Sung J.J.Y. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur. Urol. 2016;70:862–874. doi: 10.1016/j.eururo.2016.05.043. - DOI - PubMed
    1. Perez-Gracia J.L., Sanmamed M.F., Bosch A., Patiño-Garcia A., Schalper K.A., Segura V., Bellmunt J., Tabernero J., Sweeney C.J., Choueiri T.K., et al. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat. Rev. 2017;53:79–97. doi: 10.1016/j.ctrv.2016.12.005. - DOI - PubMed
    1. Pernar C.H., Ebot E.M., Wilson K.M., Mucci L.A. The Epidemiology of Prostate Cancer. Cold Spring Harb. Perspect. Med. 2018;8:a030361. doi: 10.1101/cshperspect.a030361. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Mason M., Matveev V., Wiegel T., Zattoni F., et al. EAU guidelines on prostate cancer. part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur. Urol. 2014;65:124–137. doi: 10.1016/j.eururo.2013.09.046. - DOI - PubMed

LinkOut - more resources